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Obesity is a recently established risk factor for Alzheimer’s disease (AD) and dementia. The mechanisms 
linking obesity to AD have not been firmly established and therefore no evidence-based hypotheses exist for 
designing preventative or therapeutic interventions. Adiponectin is the most abundant adipokine in the 
circulation and its levels are substantially reduced in obesity. In peripheral tissues, adiponectin exerts a wide 
range of beneficial physiological actions, including anti-diabetic, anti-inflammatory, anti-atherosclerotic and 
cardioprotective effects. Several different lines of evidence indicate that adiponectin exerts effects on the brain, 
but data is still conflicting. Recently work from our laboratory confirmed the expression of adipoR1 and 
adipoR2 in primary human astrocytes isolated from adult brain samples and we found that globular 
adiponectin induced astrocyte inflammation. Due to the prominent role of brain inflammation in AD, astrocyte 
inflammation induced by globular adiponectin could be involved in AD-related pathology. In this brief review, 
we summarized the evidence connecting obesity and AD, with a specific focus on the potential involvement of 
adiponectin. We also suggest approaches for further exploring adiponectin's effects in AD pathogenesis. 
Elucidating the role of adiponectin in AD-related pathology will hold promise for identifying potential 
therapeutics that could promote positive effects of adiponectin for the prevention and/or treatment of AD and 
dementia in the context of obesity. 
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Alzheimer's disease (AD) is characterized by 
progressive cognitive decline, loss of memory, and 
dementia, and is the most common neurodegenerative 
disease in humans. The pathological hallmarks of the 
disease are neurofibrillary tangles (NFTs) comprised of 
hyperphosphorylated tau[1] and senile plaques comprised of 
amyloid beta (Aβ)[2], which result in neuronal death and 
dysfunction. A significant inflammatory component is also 
present in brains of individuals with AD, consisting of 
activated microglia and astrocytes and an increase in levels 
of brain cytokines[3-4].The disclosure of AD presents a great 
challenge because it not only affects patients’ quality of life 
but also has significant impact on family members and 
caregivers. At present, neither a satisfying therapy nor a 
preventative cure is available for AD. This is largely 
because our knowledge of the complex biology of AD is 
incomplete, highlighting the importance of exploring and 
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understanding new mechanisms underlying AD 
progression. 
2. Obesity and increased risk of AD 
The most significant risk factor for AD is aging but 
mounting evidence now suggest that obesity represents an 
independent risk factor for AD and related dementias[5-7]. 
Research linking obesity to AD can be summarized as 
follows: 1) Longitudinal studies report that overweight, 
obesity, and/or increased abdominal adiposity in mid-life 
result in ~1.5 to 3-fold greater risk of developing AD, 
dementia or cognitive impairment later in life[5-6, 8-10]; 2) 
Many consequences of obesity-including impaired glucose 
tolerance, type 2 diabetes (T2DM), and cardiovascular 
disease-are also risk factors for AD[11-15]. Increased risk of 
AD in obesity and T2DM is separate from vascular 
dementia and appears to persist after adjustment for 
cardiovascular risk factors such as stroke, hypertension, 
and cerebrovascular disease, suggesting an independent 
role for obesity-related metabolic dysfunction; 3) High-fat 
feeding, which is used to model obesity, results in impaired 
cognitive function in rodents[16-17] and humans[18], as well 
as increased astrogliosis[19-21], and microglial activation[17; 
19-21] in rodent brains; 4) A recent review using population 
attributable risk scores estimated that 7% of all AD cases 
in the USA can be attributed to midlife obesity[22]. Despite 
this mounting evidence supporting the association between 
obesity and increased risk of AD, the mechanistic links 
between obesity and AD brain pathology remain 
incompletely understood. 
3. Adiponectin: a potential mechanistic link between 
obesity and AD? 
3.1 Evidence gleaned from adiponectin action in 
peripheral tissues 
It is now well-accepted that adipose tissue is an active 
endocrine organ that secretes a host of hormone-like 
substances termed “adipokines”[23]. Adipose tissue 
contains adipocytes, preadipocytes, endothelial cells, and 
various immune cells and thus adipokines may originate 
from any one of these diverse cell types. Adiponectin, the 
most abundant adipokine in circulation, is thought to be 
secreted almost exclusively by adipocytes[24]. Several 
experimental and clinical studies have shown that 
adiponectin is inversely related with adiposity, resulting in 
lower circulating levels of adiponectin in obesity [25-26]. In 
peripheral tissues, adiponectin improves insulin 
sensitivity[27-28] and vascular function[29], and has anti-
atherogenic, anti-inflammatory actions[30] and 
cardioprotective effects[31]. Thus, reduced adiponectin in 
obesity could indirectly influence AD risk through 
modulation of several interrelated systemic factors. 
However, emerging, yet currently incomplete, evidence 
suggests that adiponectin may impact AD risk through 
direct effects in the brain.  
3.2 Potential beneficial effects of adiponectin in the 
central nervous system (CNS) 
Adiponectin receptors are widely distributed in the 
CNS[32-34]. Recent studies show that circulating adiponectin 
enters the brain fluid from the circulation, and the trimer 
and hexamer forms of adiponectin can be detected in the 
cerebrospinal fluid[35-38]. Lee et al.[39] reported that 
adiponectin knockout (KO) mice have enhanced kainic 
acid-induced seizure severity, but only when animals are 
rendered obese through high-fat feeding. This provided the 
first evidence suggesting that adiponectin could link 
obesity-related metabolic dysfunction to greater risk of 
neurodegeneration. Substantial associative evidence also 
supports a neuroprotective effect of adiponectin, including: 
1) Clinical and animal studies report that thiazolidinediones 
(TZDs) and omega-n-3 poly-unsaturated fatty acids 
(PUFAs) have benefits on cognitive impairment associated 
with dementia and AD[40-42]. An increase in plasma 
adiponectin is one of the most notable and common 
responses to TZDs treatment and n-3 PUFAs 
supplementation [41-42]. Thus, adiponectin might play a role 
in TZD’s and n-3 PUFAs’ beneficial effects on the brain. 2) 
Insulin resistance is another significant risk factor for AD[5, 
43]. Longitudinal studies show that insulin resistance is 
associated with increased risk of AD[44-45], increased 
amyloid Aβ plaques and NFTs[43] and hippocampal 
atrophy[46]. Adiponectin is a well-known insulin 
sensitizer[27-28]. By enhancing insulin sensitivity, 
adiponectin might reduce brain pathology and AD risk. 
Furthermore, at the cellular level, Chan et al.[33] reported 
that high concentrations of adiponectin (10 µg/ml) were 
protective against amyloid beta induced neurotoxicity in 
Sw-APP transfected SH-SY5Y cells exposed to oxidative 
stress conditions, further supporting adiponectin might be 
protective against AD. 
3.3 Potential detrimental effects ofadiponectin in the 
CNS 
In contrast to the above mentioned benefits of 
adiponectin on AD risk there is also evidence supporting a 
detrimental effect of adiponectin with regards to 
neurodegeneration. The Framingham Heart Study showed 
that individuals with higher levels of adiponectin had 
increased risk of future dementia[47]. Une et al. [48] have also 
reported elevated cerebrospinal fluid adiponectin in older 
adults with mild cognitive impairment compared to healthy 
age-matched individuals, suggesting that elevated CNS 
adiponectin tracks AD risk. A pathogenic role for 
adiponectin has also been described in ischemic stroke, 
where adiponectin receptor 1 (adipoR1) expression is 
increased and globular adiponectin (gAd) enhances 
neuronal cell death in response to glucose and oxygen 
deprivation[49]. Recently, work from our laboratory 
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confirmed the expression of adipoR1 and adipoR2 in 
primary human astrocytes isolated from adult brain 
samples and we found that gAd induced astrocyte 
inflammation[34]. Based on pharmacological inhibitor 
experiments, the induction of inflammatory cytokine 
production in astrocytes appeared mediated by several 
classical inflammatory pathways, including nuclear factor 
kappa B (NFκB), p38 mitogen-activated protein kinase 
(MAPK), c-Jun N-terminal kinase (JNK), 
phosphatidylinositide 3-kinase (PI3K), and particularly 
extracellular signal-related kinase (ERK) 1/2[34]. Thus, 
augmented brain inflammation may be a potential cellular 
mechanism linking adiponectin with the previously 
described neurodegenerative consequences[34]. Further 
studies are warranted to examine the impact of adiponectin 
on brain function in neurodegenerative disorders including 
AD. One physiological complication in studies of 
adiponectin and dementia is the association with energy 
balance. Adiponectin tends to increase in conditions of 
negative energy balance (i.e., weight loss) yet weight loss 
has been shown to be a significant predictor of impending 
dementia[50-51]. Therefore, in studies showing an 
association between increased adiponectin and cognitive 
impairment[47,48] it is possible that negative energy balance 
was a confounding factor. 
3.4 Potential approaches to further explore the action of 
adiponectin in the pathogenesis of AD 
1) Adiponectin knockout (KO) mice 
Multiple strains of adiponectin KO mice have been 
created in different laboratories[52-55]. Although phenotypes 
are somewhat variable, generally adiponectin KO mice (6-
16 wks of age) show only subtle changes in metabolic 
phenotype when fed a chow diet, e.g. slight insulin 
resistance compared to WT mice[52, 55] or normal insulin 
sensitivity[53], and no difference in body weight and food 
intake[54]. In response to HFD (≥2 wks), adiponectin KO 
mice display markedly greater fat mass, insulin resistance, 
glucose intolerance, and chronic inflammatory markers 
compared to WT littermates[52, 54-55]. A recent study 
reported that adiponectin KO mice developed marked 
fibrosingsteatohepatitis 40 wks after HFD[56]. It would be 
interesting to explore whether adiponectin KO mice will 
develop more AD related pathology under chow and HFD 
conditions compared to age matched WT control.  
2) Commercially available adiponectin peptides for in 
vitro or infusion studies 
Adiponectin exists in different conformations including 
trimer, hexamer and high-molecular weight forms[57] as 
well as a globular isoform, which is produced after 
proteolytic cleavage of full-length adiponectin monomers 
by neutrophil elastase[58]. Different isoforms of adiponectin 
have been shown to play distinct biological roles in 
peripheral tissues[59-60]. Our recently published data suggest 
that globular adiponectin (1μg/ml) induces a pro-
inflammatory state in human astrocytic U373 MG cell 
line[34], which is in consistent with the findings about 
globular adiponectin in peripheral tissues[61-62]. This data 
suggesting a link between globular adiponectin and AD-
related brain pathology (i.e., inflammation) is consistent 
with studies reporting that globular adiponectin enhances 
neuronal death under hypoxic conditions[49]. The roles 
played by other forms of adiponectin in neuroinflammation 
and neurodegeneration require further exploration. Future 
cellular research is also needed to study potential 
interactions between the different forms of adiponectin and 
other established signaling molecules in AD-related 
pathology. 
3) Adipose tissue conditioned media (ATCM): a model 
of adipose-brain crosstalk? 
Adiponectin is one of the most abundant proteins in 
serum, circulating in the μg/ml range. The physiological 
levels of adiponectin in human cerebrospinal fluid are 
reported to be ~1000-fold less than in serum[63]. It is of 
importance to explore how adiponectin, at physiological 
levels, exert its action in the CNS, as well as determining 
the function of adiponectin in combination with other 
adipokines. In this regard, human adipose tissue 
conditioned media provides a unique way to explore 
potential adipose-brain crosstalk. Adipose tissue organ 
culture (ATOC) is a well-recognized technique to study 
adipose tissue function that maintains the complex 
interplay of cells that is representative of normal 
physiology [64]. ATOC is a relatively easy technique and 
cultures can be prepared from surgical or biopsy samples[64] 
from different adipose tissue depots. ATCM can be stored 
at -80C and further utilized for transferring to different cell 
lines (such as neuronal or glial cell cultures). This 
technique allows the paracrine and/or autocrine interactions 
between adipocytes and other cell types in adipose tissue to 
remain intact and is arguably more representative of what 
is seen in vivo compared to isolated adipocyte preparations. 
Thus, altered adipokine secretion from subjects with 
different metabolic status (such as lean vs. obese, and non-
T2DM vs. T2DM) can be prepared and ATCM can be used 
to treat brain cell cultures to study how physiological 
combinations of adipokines impact mechanisms of 
neurodegeneration. Because adipose tissue remains 
buoyant and floats during ATOC procedures, direct co-
culture of adipose with adherent brain cell lines can also be 
performed with, or without, the use of tissue culture inserts. 
These techniques will be potentially useful for exploring 
whether altered adipose tissue secreted factors (especially 
decreased adiponectin secretion) owing to different 
metabolic status are involved in the pathogenesis of AD. 
Because depot-specific differences in adipose tissue remain 
during the culture procedure [65], this approach will be 
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potentially helpful for determining whether fat from 
different depots might have different roles in AD pathology. 
4. Final remarks 
Given the alarming rates of obesity worldwide, 
understanding the mechanisms underlying the increased 
risk of AD in obesity is essential to develop evidence-based 
therapies for mitigating AD risk. Adiponectin may act 
locally or systemically, influencing numoerous biological 
processes including energy metabolism, insulin sensitivity, 
vascular function, neuroendocrine function and immune 
responses. Several different lines of evidence, from 
longitudinal cohort studies in humans[47] to mechanistic 
studies in cell culture[33-34] indicate that adiponectin exerts 
effects on the brain, but data is still conflicting and further 
studies are needed to clarify the precise actions of 
adiponectin in the CNS. Elucidating the role of adiponectin 
in AD-related pathology will hold promise for identifying 
potential therapeutics (e.g. pharmacological induction of 
adiponectin, targeted lifestyle strategies) that could 
promote positive effects of adiponectin for the prevention 
and/or treatment of AD and dementia in the context of 
obesity. 
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